Abstract
Objective. To study the role of cachectin and annexin V (AN-V) as a cause for preterm birth against the background of fetoplacental insufficiency formation. Patients and methods. A total of 134 pregnant women without extragenital pathology who gave birth prematurely were examined. The women were divided into three groups: group 1 included 45 women who had early preterm birth (EPB) (between 28–32 weeks and 6 days), group 2 – 42 women who had preterm birth (PB) (between 34-36 weeks and 6 days), and group 3 (control) – 47 women who had full-term pregnancy. Results. Low levels of cachectin (38.95 pg/mL) against high levels of AN-V (0.78 pg/mL) were found among patients with EPB. On the contrary, high levels of both cachectin (77.75 pg/mL) and AN-V (0.75 pg/mL) were observed in PB, indicating an important role of these cellular bioregulators in the labor onset and placentogenesis. Conclusion. The quantitative parameter of cachectin is one of the biochemical markers of preterm birth (between 28–36 weeks and 6 days of gestation) and can be used as an additional prognostic marker of this pathology, and AN-V can serve as a criterion for evaluating placentogenesis. Key words: cachectin, annexin V, preterm birth, fetoplacental
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
